GlassScriptPhysician profile
Thinh Quoc Chau
NPI 1811448251
$14,819.65
in general payments reported to CMS, 2019-2025
27 companies · $7,834 in 2025
The $7,834 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $2,063 · 2023: $3,178 · 2024: $1,294 · 2025: $7,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,075 · Consulting Fee: $1,786 · Travel and Lodging: $1,173 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,075.35 |
| Consulting Fee | $1,785.60 |
| Travel and Lodging | $1,172.59 |
| Education | $272.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,977.98 | 2021-2025 | |
| Ucb, INC. | $1,895.33 | 2022-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,601.15 | 2023-2025 | Revolve, Natrelle Saline-Filled Breast Implants, Botox |
| Janssen Biotech, INC. | $1,183.71 | 2021-2025 | Tremfya, Stelara, Simponi |
| Janssen Scientific Affairs, LLC | $1,014.04 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $928.70 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $649.63 | 2024-2025 | Dupixent |
| Incyte Corporation | $643.27 | 2023-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $520.32 | 2024-2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $464.39 | 2022-2025 | Sotyktu |
| Amgen INC. | $418.85 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $382.44 | 2022-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $303.73 | 2024 | Vtama |
| Lilly USA, LLC | $295.28 | 2023-2025 | Ebglyss, Taltz |
| Pfizer INC. | $285.15 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $266.55 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.95 | 2022-2023 | |
| Organon LLC | $193.36 | 2025 | Vtama |
| Revance Therapeutics, INC. | $150.47 | 2024-2025 | Daxxify |
| Blueprint Medicines Corporation | $103.73 | 2025 | |
| Arcutis Biotherapeutics, INC. | $85.40 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $67.29 | 2025 | |
| Lnhc, INC | $37.32 | 2025 | Zelsuvmi |
| Ani Pharmaceuticals, INC. | $34.91 | 2025 | Purified Cortrophin Gel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.39 | 2025 | Jublia, Cabtreo |
| Botanix Sb INC | $22.86 | 2025 | Sofdra |
| Pierre Fabre Pharmaceuticals, INC. | $19.45 | 2023 | Hemangeol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thinh Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.